Closed · RFA-DA-23-003 · CFDA 93.279 · Discretionary
Investigating Transposable Elements and Mobile DNA as Targets of Integration for Establishing HIV Reservoirs in the Brain (R61/R33 - Clinical Trial Optional)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- August 3, 2022
- Close date
- -
- Expected awards
The verdict
Investigating Transposable Elements and Mobile DNA as Targets of Integration for Establishing HIV Reservoirs in the Brain (R61/R33 - Clinical Trial Optional) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number.
- Varies
- award range
- Closed
- application status
- 93.279
- CFDA program
Opportunity snapshot. This Grants.gov announcement - Investigating Transposable Elements and Mobile DNA as Targets of Integration for Establishing HIV Reservoirs in the Brain (R61/R33 - Clinical Trial Optional) - is cataloged under number RFA-DA-23-003 and tied to CFDA assistance listing 93.279, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on February 11, 2022. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Varies by applicant. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on August 3, 2022. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Varies by applicant
Close Date
August 3, 2022
Posted
February 11, 2022
Instrument
Grant
Description
oMany substances of abuse, including cocaine, methamphetamine, and several opioids exert powerful environmental insults on genomic DNA in the brain that induce expression of transposable elements and other mobile DNA. Transposable elements and mobile DNA, which comprise almost 50% of the human genome, are typically silenced through strong epigenetic modifications. When transposable elements and mobile DNA become active in people who use drugs of abuse, they potentially provide multiple integration sites for HIV in microglia. HIV integration into these unstable regions could lead to major chromosomal rearrangements and global dysregulation of transcription, ultimately contributing to HIV-associated Neurocognitive Disorder (HAND) and providing a mechanism by which drugs of abuse increase the probability of reactivating microglial HIV reservoirs. Understanding the factors that influence HIV integration in these microglial reservoirs is crucial to developing next-generation HIV therapies and potential cures. This concept addresses these gaps by fostering studies aimed at providing a deeper understanding of the complex interplay among HIV, substances of abuse, inflammation, and disease progression.
Eligibility
Grants.gov lists this opportunity under eligibility category codes 00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 25. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Drug Abuse Research Programs
National Institutes of Health
Agency Contact
NIH OER Webmaster OERWebmaster03@od.nih.gov
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |